Vaxil BioTherapeutics

Vaxil BioTherapeutics Ltd. is a clinical-stage biotechnology company based in Toronto, Canada, that specializes in immunotherapy aimed at treating infectious diseases and cancer. The company utilizes a novel drug discovery platform centered on signal peptides, which allows for the development of synthetic therapeutic and preventive vaccines that activate both T and B cells. Vaxil's lead product, ImMucin, has successfully completed a Phase I/II clinical trial for the treatment of multiple myeloma. Additionally, the company is engaged in developing a tuberculosis vaccine and a coronavirus vaccine, collaborating with The Tel Aviv Sourasky Medical Center and the U.S. Army Medical Research Institute of Infectious Diseases for research and testing. Founded in 2006, Vaxil BioTherapeutics is committed to advancing its innovative vaccine technologies to improve patient outcomes in immuno-oncology and infectious disease management.